Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 1097 - 1104 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC5084 | K02288 |
|
Potent and selective inhibitor of type I bone morphogenic protein (BMP) receptors (IC50 values are 1.1, 1.8, 6.4, 34.4, 220, 302 and 321 nM for ALK2, ALK1, ALK6, ALK3, ActRIIA, ALK4 and ALK5 respectively). Reduces BMP4-induced Smad1/5/8 phosphorylation in vitro (IC50 = 100 nM) and induces dorsalization of zebrafish embryos.
|
|
| BCC5085 | LY364947 |
|
Selective inhibitor of TGF-<span class='symbol'>β</span> type-I receptor (TGF-<span class='symbol'>β</span> RI, TGFR-I, T<span class='symbol'>β</span>R-I, ALK-5) (IC<sub>50</sub> values are 59, 400 and 1400 nM for TGR-<span class='symbol'>β</span> RI, TGF-<span class='symbol'>β</span> RII and MLK-7K respectively). Inhibits TGF-<span class='symbol'>β</span>-dependent luciferase production in mink lung cells (p3TP lux) and growth in mouse fibroblasts (NIH 3T3) (IC<sub>50</sub> values are 47 and 89 nM respectively). Suppresses invasion of MDA-MB-231 breast cancer cells in a matrigel invasion assay.
|
|
| BCC5086 | Pirfenidone |
|
Antifibrotic agent, effective in models of pulmonary and lung fibrosis. Inhibits collagen production and fibroblast proliferation. Regulates cytokine levels following oral administration in vivo. Potent scavenger of free radicals and inhibitor of lipid peroxidation.
|
|
| BCC5087 | SB505124 |
|
Selective inhibitor of transforming growth factor-<span class='symbol'>β</span> type I receptor (ALK5), ALK4 and ALK7 (IC<sub>50</sub> values are 47 and 129 nM for ALK5 and ALK4 respectively). Selectively inhibits signaling from TGF-<span class='symbol'>β</span> and activin; does not inhibit other ALK family members.
|
|
| BCC5088 | Beta-Lapachone |
|
DNA topoisomerase I inhibitor. Exhibits a different inhibitory mechanism to camptothecin. Induces apoptosis in a variety of cell lines, including prostate cancer and promyelocytic leukemia cells; blocks the cell cycle in G<sub>0</sub>/G<sub>1</sub>. Also has effects on DNA topoisomerase II, NF-<span class='symbol'>κ</span>B, AP-1, and JNK.
|
|
| BCC5093 | GW441756 |
|
Potent, selective inhibitor of the NGF receptor tyrosine kinase A (TrkA) (IC50 = 2 nM). Displays > 100-fold selectivity over a range of other kinases.
|
|
| BCC5096 | Tolvaptan |
|
Potent and selective competitive vasopressin V2 receptor antagonist (Ki values are 0.06 and 12.3 nM for V2 and V1a receptors respectively). Decreases urine osmolality and increases serum sodium concentrations. Delays the onset of end-stage renal disease in a mouse model of polycystic kidney disease. Exhibits myocardial and renal protective effects in hypertensive heart failure rats. Orally active.
|
|
| BCC5098 | ZM 323881 HCl |
|
Potent and selective inhibitor of human vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) activity. Selectively inhibits VEGFR-2 (IC<sub>50</sub> = 2 nM) over VEGFR-1 and a range of other receptor tyrosine kinases such as PDGFR<span class='symbol'>β</span>, FGFR1, EGFR and erbB2 (IC<sub>50</sub> > 50 <span class='symbol'>μ</span>M). Inhibits VEGF-A-induced endothelial cell proliferation <em>in vitro</em> (IC<sub>50</sub> = 8 nM).
|
|